Scholar Rock said Tuesday that the Food and Drug Administration rejected its treatment for the muscle-wasting disease spinal muscular atrophy due t o long-unresolved problems , including pest contamination, at a contract manufacturing facility where the drug is packaged.

The Cambridge, Mass.-based biotech said its drug will be resubmitted to the FDA for approval once the quality-control issues at the manufacturing facility, owned by the Danish pharma giant Novo Nordisk, are cleared.

Scholar Rock offered no timeline for its drug, called apitegromab, however, reflecting uncertainty over how quickly Novo can work to get its facility back into the good graces of the FDA.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page